Literature DB >> 8306120

Personality disorders in patients with somatisation disorder. A controlled study.

J Stern1, M Murphy, C Bass.   

Abstract

Twenty-five women with somatisation disorder (SD) were compared with matched patient controls for the presence of personality disorders. Personality was assessed with the Personality Assessment Schedule (PAS). Interviewers were unaware of the patients' diagnoses. All controls had DSM-III-R axis I diagnoses of depressive or anxiety disorders. The prevalence of personality disorders among patients with somatisation disorder was 72% compared with 36% among controls. Certain personality disorders, including passive-dependent, histrionic, and sensitive-aggressive, occurred significantly more often in the SD patients than controls.

Entities:  

Mesh:

Year:  1993        PMID: 8306120     DOI: 10.1192/bjp.163.6.785

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  5 in total

1.  Abdominal pain of psychotic origin.

Authors:  Z Khan; J Stern; A Forbes
Journal:  J R Soc Med       Date:  1997-04       Impact factor: 5.344

2.  DOES HAVING A DYSFUNCTIONAL PERSONALITY HURT YOUR CAREER? AXIS II PERSONALITY DISORDERS AND LABOR MARKET OUTCOMES.

Authors:  Susan L Ettner; Johanna Catherine Maclean; Michael T French
Journal:  Ind Relat (Berkeley)       Date:  2011-01

3.  Enhanced Connectivity of Thalamo-Cortical Networks in First-Episode, Treatment-Naive Somatization Disorder.

Authors:  Jin Zhao; Qinji Su; Feng Liu; Zhikun Zhang; Ru Yang; Wenbin Guo; Jingping Zhao
Journal:  Front Psychiatry       Date:  2020-09-11       Impact factor: 4.157

Review 4.  Medically unexplained symptoms: exacerbating factors in the doctor-patient encounter.

Authors:  L A Page; S Wessely
Journal:  J R Soc Med       Date:  2003-05       Impact factor: 18.000

5.  Classification and diagnosis of patients with medically unexplained symptoms.

Authors:  Robert C Smith; Francesca C Dwamena
Journal:  J Gen Intern Med       Date:  2007-05       Impact factor: 5.128

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.